PharmTech Drug Digest 11.20
News|Articles|January 6, 2014

Testosterone-Regulated Genes May Affect Vaccine Immunity

A study led by Stanford University explains why men may have weaker responses to vaccines than women.

A new study has identified a link between certain genes affected by testosterone and antibody responses to an influenza vaccine. The findings suggest that testosterone levels may partially explain why men often have weaker responses to vaccines than women. The study, led by researchers at Stanford University, was supported in part by the National Institute of Allergy and Infectious Diseases, a component of the National Institutes of Health was published in Proceedings of the National Academy of Sciences.

Previous research has shown that men typically experience more severe viral and other microbial infections than women, who tend to mount stronger immune responses to infections and vaccinations. In the new study, researchers analyzed the antibody responses of 53 women and 34 men of various ages to the 2008-2009 seasonal influenza vaccine. Compared to the men, the women produced antibodies that in laboratory tests could more effectively neutralize the influenza virus.


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.